ArticleEndocrine2026
Management of persistent and recurrent Cushing's disease: Efficacy of repeat transsphenoidal surgery.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTranssphenoidal surgery (TSS) is the treatment of choice for Cushing's disease (CD). In experienced pituitary centers a high remission rate is reported. Nevertheless, endocrinologists and neurosurgeons face cases with persistent or recurrent CD. In addition to medical treatment, radiation therapy and bilateral adrenalectomy, repeat TSS must also be considered. This study evaluates outcomes and predictors of remission following repeat TSS in patients with CD.
methodsA retrospective single-center analysis was conducted including all patients who underwent re-TSS for persistent (n = 29) or recurrent (n = 42) CD between 2004 and 2024. Clinical, radiological, intraoperative, and biochemical data were analyzed for factors influencing remission and long-term outcome.
resultsRemission was achieved in 75.4% at first follow-up and 55.7% at long-term follow-up; early/long-term remission was 70.8%/50.0% after surgery for persistence and 78.4%/59.5% after surgery for recurrence. First reoperation yielded higher remission than those with ≥ 2 prior surgeries (81.6% vs. 50.0%, p = 0.030). Invasive tumor growth was strongly associated with reduced remission (p = 0.001). Selective adenomectomy or adenomectomy with rim excision achieved the highest early remission, whereas subtotal or purely explorative resections were less effective (p = 0.011), indicating that targeted resection of an identifiable lesion improves outcome. Postoperative complications occurred in 14.1% (10/71); major complications in 8.5% (6/71); there was no perioperative mortality.
conclusionRepeat TSS is a safe and effective treatment for both persistent and recurrent CD in specialized pituitary centers. Surgical success depends on tumor invasiveness, prior operations, and surgical strategies. Reoperation should be considered an essential part of individualized, multidisciplinary management to achieve sustained remission.
Indexed as
Identifiers
42081125What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.